Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug VIS171 takes first step in human trials for autoimmune conditions

NCT ID NCT05418101

First seen Apr 22, 2026 · Last updated May 20, 2026 · Updated 8 times

Summary

This early-stage study tested a new drug, VIS171, in 61 people to see if it is safe. First, healthy volunteers received a single dose. Then, people with autoimmune diseases received multiple doses. The main goal was to check for side effects and how the drug affects immune cells. This is a first step to see if VIS171 might help control autoimmune diseases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ambulatory for Specialized Medical Help - skin and venereal diseases

    Sofia, 1407, Bulgaria

  • Clinical republican Hospital

    Chisinau, MD 2025, Moldova

  • Comac Medical Ltd

    Sofia, 1612, Bulgaria

  • Diagnostic and Consultative Center Convex EOOD

    Sofia, 1680, Bulgaria

  • MBAL Sveta Sofia

    Sofia, 1618, Bulgaria

  • New Zealand Clinical Research

    Christchurch, 8011, New Zealand

  • Radboud University Medical Center

    Gelderland, 6525, Netherlands

  • UMHAT

    Plovdiv, 4002, Bulgaria

  • Universitaetsklinikum Bonn AöR

    Bonn, 53127, Germany

  • Universitätsmedizin der Johannes-Gutenberg-Universität Mainz

    Rheinland-Pfalz, 55131, Germany

Conditions

Explore the condition pages connected to this study.